11 Best Pharma Stocks to Buy According to Hedge Funds

8. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 74

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19. Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

The company reported a 6% year-over-year growth in its fiscal Q4 2024 revenue, which reached $7.6 billion. Its GAAP EPS reflected a year-over-year increase of roughly 25%, while its adjusted EPS rose around 10.5% year-over-year to $1.90, surpassing analyst estimates.

The company’s HIV sales also present a positive picture, rising 8% in 2024 to $19.6 billion and exceeding its expectations of a 5% growth. Full-year sales for Biktarvy, an HIV treatment, rose 13%. Gilead Sciences, Inc. (NASDAQ:GILD) has established a track record of consistently strong growth in its HIV business, undergoing a 5% growth in 2022, 6% in 2023, and 8% in 2024. This growth is attributed to its strong execution and the strength of its innovation.

In addition to these strong results, Gilead Sciences, Inc. (NASDAQ:GILD) announced upbeat 2025 guidance, expecting significantly higher numbers and improved performance. Management expects non-GAAP diluted EPS of between $7.70 and $8.10, versus $4.62 for full-year 2024.